BRICS health ministers agree to improve access to low-cost medicines

NewsGuard 100/100 Score

Health ministers from Brazil, Russia, India, China, and South Africa in Beijing "on Monday vowed to improve access to low-cost and high-quality medicine - and called on developed nations to shoulder responsibility in helping the poor," Agence France-Presse reports (7/11).

"We agree to establish and encourage a global health agenda for universal access to affordable medicines and health commodities," according to a statement from the ministers of the so-called BRICS nations, Deutsche Presse-Agentur/M&C writes. "They urged increased access to 'new and innovative antiretroviral therapies ... to accelerate progress towards universal access to HIV prevention, treatment, care, and support,'" as well as "better treatment and research for tuberculosis and malaria and greater access to diagnosis and treatment of viral hepatitis," the news service notes (7/12).

"The meeting Monday was the first ministerial-level meeting of health officials from the bloc of emerging countries. The five BRICS members account for 40 percent of the world's population," the Associated Press/Forbes writes (7/11).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis